RPP Reseach and Partnership Platform Contribution By Dr Sven - - PDF document

▶
rpp reseach and partnership platform contribution by dr
SMART_READER_LITE
LIVE PREVIEW

RPP Reseach and Partnership Platform Contribution By Dr Sven - - PDF document

Jan 23, 2023 748 likes •844 views

Intergovernmental Group of Experts on Competition Law and Policy, Fifteenth Session Geneva, 19-21 October 2016 RPP Reseach and Partnership Platform Contribution By Dr Sven Gallasch Centre for Competition Policy, United Kingdom Dr Mor Bakhoum -

slide-1
SLIDE 1

Intergovernmental Group of Experts on Competition Law and Policy, Fifteenth Session Geneva, 19-21 October 2016 RPP Reseach and Partnership Platform Contribution By Dr Sven Gallasch Centre for Competition Policy, United Kingdom Dr Mor Bakhoum - Max Planck Institute for Innovation and Competition, Germany

The views expressed are those of the author(s) and do not necessarily reflect the views of UNCTAD

slide-2
SLIDE 2

Increasing the access to affordable medicine in developing countries and LDCs: between regulation and competition

competitionpolicy.ac.uk Dr Sven Gallasch Centre for Competition Policy, United Kingdom Dr Mor Bakhoum Max Planck Institute for Innovation and Competition, Germany

slide-3
SLIDE 3

Background

Developed world

  • Complex interplay of IP/Competition/pharma regulations
  • Brand/generic dichotomy
  • Prone to regulatory gaming – pharma antitrust

Developing world

  • same dichotomy not necessarily applicable
  • Less prevalent interplay – to a certain extent unknown
  • How to increase access to affordable medicines through regulation and

competition while avoiding regulatory gaming

slide-4
SLIDE 4

Project – main research objectives

  • 1. The status quo: identifying the relevant framework
  • 2. Identifying barrier for entry to the pharmaceutical market
  • 3. Providing advice on the improvement of access to affordable

medicine

slide-5
SLIDE 5

Project – the approach

  • 1. Data collection

Creation of panel data set through questionnaires, surveys and structured interviews

  • 2. Empirical research

Qualitative data analysis on a country by country basis and later on comparative basis

  • 3. Policy recommendations

min: comprehensive overview of access max: compare and delineate individual approaches

slide-6
SLIDE 6

Project – categories of variables

  • Pharmaceutical regulations
  • Incl. marketing authorisation, drug price regulation, substitution laws, parallel

trade

  • Competition legislation
  • Incl. US/EU model, policy goals, covering regulated markets, IP exemption,

enforcement level, compulsory licensing

  • IP legislation
  • Incl. TRIPS, patent enforcement system (bifurcation)
slide-7
SLIDE 7

Project – categories of variables (cont)

  • Procurement
  • Sector specific information
  • Incl. supply side, demand side (buyer power, distribution, public/private

health)

  • Anticompetitive conduct
slide-8
SLIDE 8

Questions and suggestions?

Please contact us: Sven Gallasch s.gallasch@uea.ac.uk Mor Bakhoum mor.bakhoum@ip.mpg.de